TECH Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 14.91%. Bio-Techne Corp.'s return on equity of 3.85% beat Boston Scientific Corp.'s return on equity of 12.46%.

Bio-Techne Corp. has a consensus price target of $70.00, signalling upside risk potential of 2.7%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 34.48%. Given that Boston Scientific Corp. has higher upside potential than Bio-Techne Corp., analysts believe Boston Scientific Corp. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.470, which suggesting that the stock is 47.016% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.47%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Bio-Techne Corp.'s net income of $38.2M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 139.33x while Boston Scientific Corp.'s PE ratio is 49.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 8.83x versus 7.14x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 27.89%. Bio-Techne Corp.'s return on equity of 3.85% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Bio-Techne Corp. has a consensus price target of $70.00, signalling upside risk potential of 2.7%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $606.43 which suggests that it could grow by 15.73%. Given that Intuitive Surgical, Inc. has higher upside potential than Bio-Techne Corp., analysts believe Intuitive Surgical, Inc. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.470, which suggesting that the stock is 47.016% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.47%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Bio-Techne Corp.'s net income of $38.2M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 139.33x while Intuitive Surgical, Inc.'s PE ratio is 66.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 8.83x versus 18.88x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular, Inc. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 28.44%. Bio-Techne Corp.'s return on equity of 3.85% beat LeMaitre Vascular, Inc.'s return on equity of 15.17%.

Bio-Techne Corp. has a consensus price target of $70.00, signalling upside risk potential of 2.7%. On the other hand LeMaitre Vascular, Inc. has an analysts' consensus of $103.67 which suggests that it could grow by 23.09%. Given that LeMaitre Vascular, Inc. has higher upside potential than Bio-Techne Corp., analysts believe LeMaitre Vascular, Inc. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.470, which suggesting that the stock is 47.016% more volatile than S&P 500. In comparison LeMaitre Vascular, Inc. has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.925%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.47%. LeMaitre Vascular, Inc. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.20 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. LeMaitre Vascular, Inc. pays out 33.1% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are larger than LeMaitre Vascular, Inc. quarterly revenues of $61M. Bio-Techne Corp.'s net income of $38.2M is higher than LeMaitre Vascular, Inc.'s net income of $17.4M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 139.33x while LeMaitre Vascular, Inc.'s PE ratio is 36.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 8.83x versus 8.14x for LeMaitre Vascular, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of -8.49%. Bio-Techne Corp.'s return on equity of 3.85% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

Bio-Techne Corp. has a consensus price target of $70.00, signalling upside risk potential of 2.7%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $25.71 which suggests that it could grow by 29.22%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Bio-Techne Corp., analysts believe Tandem Diabetes Care, Inc. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.470, which suggesting that the stock is 47.016% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.47%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Bio-Techne Corp.'s net income of $38.2M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 139.33x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 8.83x versus 1.32x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.